UMB, MedImmune agree to collaborate

The University of Maryland, Baltimore and MedImmune Inc., of Gaithersburg, a subsidiary of British drug maker AstraZeneca PLC, announced they have entered into a five-year, $6 million agreement to work on novel bioscience research in Maryland.

Leave a Reply

Your email address will not be published. Required fields are marked *